NCT00193557View on ClinicalTrials.gov

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

January 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Trial Locations (2)

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00193557 - Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter